N1-(3-(哌啶-1-基)丙基)苯-1,2-二胺 | 115581-67-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N1-(3-(哌啶-1-基)丙基)苯-1,2-二胺
• 英文名称: N-(3-piperidino-propyl)-o-phenylenediamine
• 英文别名: N-(3-Piperidino-propyl)-o-phenylendiamin；N-[3-(1-piperidinyl)propyl]-o-phenylenediamine；N1-(3-(piperidin-1-yl)propyl)benzene-1,2-diamine；2-N-(3-piperidin-1-ylpropyl)benzene-1,2-diamine
• CAS: 115581-67-4
• 化学式: C₁₄H₂₃N₃
• 分子量: 233.357
• InChiKey: IWMNXRQYGIBEDW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  41.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  溴化氰 、 N1-(3-(哌啶-1-基)丙基)苯-1,2-二胺 以 水 、 异丙醇 为溶剂， 生成 1-(3-piperidin-1-yl-propyl)-1H-benzoimidazol-2-ylamine
  参考文献：
  名称：

  Anti-inflammatory 1-[3-(dialkylamino)propyl]-2-acylaminobenzimidazoles

  摘要：

  1-[3-(二烷基氨基)丙基]-2-酰胺基苯并咪唑和2-酰胺基氨基-3-[3-(二烷基氨基)丙基]咪唑并[4,5-b]吡啶以及它们与药用可接受的酸盐，是一类新型化合物，在治疗炎症性疾病中有用。提供了替代制备方法，并详细描述了主要的合成途径。

  公开号：

  US04002623A1
• 作为产物：
  描述：

  1-(3-氨基丙基)哌啶 在 溶剂黄146 、 锌 作用下， 以 四氢呋喃 为溶剂， 反应 13.0h， 生成 N1-(3-(哌啶-1-基)丙基)苯-1,2-二胺
  参考文献：
  名称：

  Design, synthesis and biological evaluation of novel 7-alkylamino substituted benzo[a]phenazin derivatives as dual topoisomerase I/II inhibitors

  摘要：

  A novel series of benzo[a]phenazin derivatives bearing alkylamino side chains were designed, synthesized and evaluated for their topoisomerases inhibitory activity as well as cytotoxicity against four human cancer cell lines (HL-60, K-562, HeLa, and A549). These compounds were found to be dual inhibitors of topoisomerase (Topo) I and Topo II, and exhibited excellent antiproliferative activity, in particular against HL-60 cells with submicromolar IC50 values. Further mechanistic studies showed that this class of compounds acted as Topo I poisons by stabilizing the Topo I-DNA cleavage complexes and Topo II catalytic inhibitors by inhibiting the ATPase activity of hTopo II. Molecular docking studies revealed the binding modes of these compounds for Topo I and Topo II. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.01.024

文献信息

• 2-Acylamino-3-[3-(dialkylamino)propyl]imidazo[4,5-b]pyridines
  申请人：Pfizer

  公开号：US04059584A1

  公开（公告）日：1977-11-22

  1-[3-(Dialkylamino)propyl]-2-acylaminobenzimidazoles and 2-acylamino-3-[3-(dialkylamino)propyl]imidazo[4,5-b]pyridines and salts thereof with pharmaceutically acceptable acids, a novel class of compounds useful in the treatment of inflammatory conditions. Alternate methods of preparation are provided and the primary synthetic route is described in detail.

  1-[3-(二烷基氨基)丙基]-2-酰胺基苯并咪唑和2-酰胺基-3-[3-(二烷基氨基)丙基]咪唑[4,5-b]吡啶及其与药学上可接受的酸盐是一种新的化合物类别，可用于治疗炎症疾病。提供了替代制备方法，并详细描述了主要的合成路线。
• Heterocyclic Basic Compounds. VII. Basically-substituted Isoalloxazine Derivatives¹
  作者：Robert R. Adams、Charles A. Weisel、Harry S. Mosher

  DOI：10.1021/ja01209a055

  日期：1946.5
• US4002623A
  申请人：——

  公开号：US4002623A

  公开（公告）日：1977-01-11
• US4059584A
  申请人：——

  公开号：US4059584A

  公开（公告）日：1977-11-22
• Design, synthesis and biological evaluation of novel 7-alkylamino substituted benzo[a]phenazin derivatives as dual topoisomerase I/II inhibitors
  作者：Bing-Lei Yao、Yan-Wen Mai、Shuo-Bin Chen、Hua-Ting Xie、Pei-Fen Yao、Tian-Miao Ou、Jia-Heng Tan、Hong-Gen Wang、Ding Li、Shi-Liang Huang、Lian-Quan Gu、Zhi-Shu Huang

  DOI：10.1016/j.ejmech.2015.01.024

  日期：2015.3

  A novel series of benzo[a]phenazin derivatives bearing alkylamino side chains were designed, synthesized and evaluated for their topoisomerases inhibitory activity as well as cytotoxicity against four human cancer cell lines (HL-60, K-562, HeLa, and A549). These compounds were found to be dual inhibitors of topoisomerase (Topo) I and Topo II, and exhibited excellent antiproliferative activity, in particular against HL-60 cells with submicromolar IC50 values. Further mechanistic studies showed that this class of compounds acted as Topo I poisons by stabilizing the Topo I-DNA cleavage complexes and Topo II catalytic inhibitors by inhibiting the ATPase activity of hTopo II. Molecular docking studies revealed the binding modes of these compounds for Topo I and Topo II. (C) 2015 Elsevier Masson SAS. All rights reserved.